31 , 32 Azacitidine and panobinostat showed a trend to improving global health status and patient-reported fatigue in clinical responders after six cycles, suggesting potential for QoL benefits in patients receiving this epigenetic-modifying regimen.
← all excerpts
Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.
1
—
—